<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00103272</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01463</org_study_id>
    <secondary_id>OSU 0448</secondary_id>
    <secondary_id>NCI-6520</secondary_id>
    <secondary_id>CDR0000409584</secondary_id>
    <secondary_id>OSU-2004C0084</secondary_id>
    <secondary_id>OSU-0448</secondary_id>
    <secondary_id>U01CA076576</secondary_id>
    <nct_id>NCT00103272</nct_id>
  </id_info>
  <brief_title>17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer</brief_title>
  <official_title>A Phase I Study of PS-341 (Velcade, Bortezomib) in Combination With 17-allylamino-17-demethoxygeldanamycin (17-AAG) in Patients With Relapsed or Refractory Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects and best dose of&#xD;
      17-N-allylamino-17-demethoxygeldanamycin and bortezomib in treating patients with relapsed or&#xD;
      refractory hematologic cancer. Drugs used in chemotherapy, such as&#xD;
      17-N-allylamino-17-demethoxygeldanamycin, work in different ways to stop the growth of cancer&#xD;
      cells, either by killing the cells or by stopping them from dividing. Bortezomib may stop the&#xD;
      growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving&#xD;
      17-N-allylamino-17-demethoxygeldanamycin together with bortezomib may kill more cancer cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the maximum tolerated dose (MTD) of PS-341 (Velcade, Bortezomib) in&#xD;
      combination with 17-allyamino-17-demethoxygeldanamycin (17-AAG) in patients with relapsed or&#xD;
      refractory acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL).&#xD;
&#xD;
      II. To determine the MTD of PS-341 in combination with 17-AAG in patients with relapsed or&#xD;
      refractory chronic lymphocytic leukemia (CLL), and non-Hodgkin's lymphoma (NHL).&#xD;
&#xD;
      III. To define the specific toxicities and the dose limiting toxicity (DLT) of PS-341 in&#xD;
      combination with 17-AAG in the treatment of patients with relapsed or refractory hematologic&#xD;
      malignancies.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the pharmacokinetics of 17-AAG alone and in combination with PS-341 in&#xD;
      patients with AML, ALL, CLL, and NHL.&#xD;
&#xD;
      II. To evaluate 20S proteasome inhibition following combination therapy with 17-AAG and&#xD;
      PS-341 in patients with AML, ALL, CLL, and NHL.&#xD;
&#xD;
      III. To assess the relationship between FLT3 mutational status and leukemic cell response to&#xD;
      PS-341 and 17-AAG in patients with AML.&#xD;
&#xD;
      IV. To assess the relationship between Bcl-2 over-expression and response to 17-AAG and&#xD;
      PS-341 in patients with AML and NHL.&#xD;
&#xD;
      V. To evaluate the effects of the combination of PS-341 and 17-AAG on Hsp90 and NF-kappaB and&#xD;
      their downstream targets including Hsp70, Akt, phosphorylated Akt, p21, and caspases 3 and 9&#xD;
      in patient-derived primary AML and NHL cells.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study. Patients are stratified according to diagnosis&#xD;
      (acute myeloid leukemia [AML] or acute lymphoblastic leukemia vs chronic lymphoctyic leukemia&#xD;
      or non-Hodgkin's lymphoma [NHL]).&#xD;
&#xD;
      Patients receive 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) intravenously (IV) over&#xD;
      1-6 hours on days 1, 4, 8, and 11 and bortezomib IV over 3-5 seconds on days 4, 8, and 11 of&#xD;
      course 1 and on days 1, 4, 8, and 11 of all subsequent courses.&#xD;
&#xD;
      Treatment repeats every 21 days for 3-12 courses provided patient is receiving clinical&#xD;
      benefit. Patients achieving objective response may discontinue therapy to undergo stem cell&#xD;
      transplantation.Cohorts of 3-6 patients with receive escalating doses of 17-AAG and&#xD;
      bortezomib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the&#xD;
      dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      After the MTD is determined, an additional 20 patients (10 per stratum with AML or follicular&#xD;
      NHL) are enrolled and receive 17-AAG and bortezomib as above at the MTD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>April 2005</start_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of bortezomib) in combination with 17-AAG)</measure>
    <time_frame>Day 21</time_frame>
    <description>Defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Adult Acute Basophilic Leukemia</condition>
  <condition>Adult Acute Eosinophilic Leukemia</condition>
  <condition>Adult Acute Megakaryoblastic Leukemia (M7)</condition>
  <condition>Adult Acute Minimally Differentiated Myeloid Leukemia (M0)</condition>
  <condition>Adult Acute Monoblastic Leukemia (M5a)</condition>
  <condition>Adult Acute Monocytic Leukemia (M5b)</condition>
  <condition>Adult Acute Myeloblastic Leukemia With Maturation (M2)</condition>
  <condition>Adult Acute Myeloblastic Leukemia Without Maturation (M1)</condition>
  <condition>Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities</condition>
  <condition>Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)</condition>
  <condition>Adult Acute Myelomonocytic Leukemia (M4)</condition>
  <condition>Adult Erythroleukemia (M6a)</condition>
  <condition>Adult Pure Erythroid Leukemia (M6b)</condition>
  <condition>Anaplastic Large Cell Lymphoma</condition>
  <condition>Angioimmunoblastic T-cell Lymphoma</condition>
  <condition>Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue</condition>
  <condition>Nodal Marginal Zone B-cell Lymphoma</condition>
  <condition>Recurrent Adult Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Adult Acute Myeloid Leukemia</condition>
  <condition>Recurrent Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Recurrent Adult T-cell Leukemia/Lymphoma</condition>
  <condition>Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma</condition>
  <condition>Recurrent Grade 1 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 2 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 3 Follicular Lymphoma</condition>
  <condition>Recurrent Mantle Cell Lymphoma</condition>
  <condition>Recurrent Marginal Zone Lymphoma</condition>
  <condition>Recurrent Mycosis Fungoides/Sezary Syndrome</condition>
  <condition>Recurrent Small Lymphocytic Lymphoma</condition>
  <condition>Refractory Chronic Lymphocytic Leukemia</condition>
  <condition>Small Intestine Lymphoma</condition>
  <condition>Splenic Marginal Zone Lymphoma</condition>
  <condition>Waldenstr√∂m Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>Treatment (17-AAG and bortezomib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) IV over 1-6 hours on days 1, 4, 8, and 11 and bortezomib IV over 3-5 seconds on days 4, 8, and 11 of course 1 and on days 1, 4, 8, and 11 of all subsequent courses.&#xD;
Treatment repeats every 21 days for 3-12 courses provided patient is receiving clinical benefit. Patients achieving objective response may discontinue therapy to undergo stem cell transplantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tanespimycin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (17-AAG and bortezomib)</arm_group_label>
    <other_name>17-AAG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (17-AAG and bortezomib)</arm_group_label>
    <other_name>LDP 341</other_name>
    <other_name>MLN341</other_name>
    <other_name>VELCADE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of 1 of the following hematologic&#xD;
             malignancies:&#xD;
&#xD;
               -  Acute myeloid leukemia or acute lymphoblastic leukemia&#xD;
&#xD;
                    -  Not a candidate for potentially curative therapy&#xD;
&#xD;
                    -  WBC ‚â§ 10,000/mm^3 OR WBC ‚â§ 40,000/mm^3 that is stable for 5 days&#xD;
                       (hydroxyurea allowed)&#xD;
&#xD;
                    -  No acute promyelocytic leukemia&#xD;
&#xD;
               -  Non-Hodgkin's lymphoma (NHL), including 1 of the following subtypes:&#xD;
&#xD;
                    -  Small lymphocytic lymphoma&#xD;
&#xD;
                    -  Marginal zone lymphoma&#xD;
&#xD;
                    -  Lymphoplasmacytic lymphoma&#xD;
&#xD;
                    -  Follicular lymphoma&#xD;
&#xD;
                    -  Mantle cell lymphoma&#xD;
&#xD;
                    -  Diffuse large B-cell lymphoma&#xD;
&#xD;
                    -  Anaplastic large cell lymphoma&#xD;
&#xD;
                    -  Peripheral T-cell lymphoma&#xD;
&#xD;
                    -  Extranodal NK/T cell lymphoma (nasal and nasal type)&#xD;
&#xD;
                    -  Enteropathy-type T-cell lymphoma&#xD;
&#xD;
                    -  Hepatosplenic T-cell lymphoma&#xD;
&#xD;
                    -  Angioimmunoblastic T-cell lymphoma&#xD;
&#xD;
                    -  Subcutaneous panniculitis-like T-cell lymphoma&#xD;
&#xD;
               -  Chronic lymphocytic leukemia (CLL)&#xD;
&#xD;
          -  Patients with NHL or CLL must meet the following criteria:&#xD;
&#xD;
               -  Ineligible for, or refused potentially curative stem cell transplantation&#xD;
&#xD;
               -  Transformed lymphoma/Richter's transformation, defined as the transformation of&#xD;
                  low-grade lymphoma, including follicular lymphoma, CLL, or small lymphocytic&#xD;
                  lymphoma to high-grade lymphoma (i.e., diffuse large cell lymphoma) allowed at&#xD;
                  time of transformation&#xD;
&#xD;
               -  Evidence of ‚â• 50% bone marrow involvement at the time of enrollment OR tumor&#xD;
                  tissue accessible for biopsy (for patients enrolled after the maximum tolerated&#xD;
                  dose [MTD] is determined)&#xD;
&#xD;
               -  Absolute neutrophil count ‚â• 1,000/mm^3&#xD;
&#xD;
               -  Platelet count ‚â• 100,000/mm^3&#xD;
&#xD;
          -  Relapsed or refractory disease&#xD;
&#xD;
          -  Willing to undergo serial bone marrow biopsy (for patients enrolled after the MTD is&#xD;
             determined)&#xD;
&#xD;
          -  No untreated or active CNS leukemia or lymphoma&#xD;
&#xD;
          -  Performance status - ECOG 0-2&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
          -  Bilirubin ‚â§ 1.5 mg/dL&#xD;
&#xD;
          -  AST and ALT ‚â§ 2.5 times upper limit of normal&#xD;
&#xD;
          -  Creatinine ‚â§ 2.0 mg/dL&#xD;
&#xD;
          -  No uncontrolled cardiac disease&#xD;
&#xD;
          -  No New York Heart Association class III-IV symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular&#xD;
             fibrillation &gt; 3 beats in a row) within the past 6 months&#xD;
&#xD;
          -  No other uncontrolled cardiac arrhythmia or requiring antiarrhythmic drugs&#xD;
&#xD;
          -  No myocardial infarction within the past year&#xD;
&#xD;
          -  No active ischemic heart disease within the past year&#xD;
&#xD;
          -  No congenital long QT syndrome&#xD;
&#xD;
          -  No left bundle branch block&#xD;
&#xD;
          -  QTc ‚â• 450 msec (for men) or 470 (for women) on ECG/EKG&#xD;
&#xD;
          -  No history of LVEF &lt; 50% by MUGA or echocardiogram&#xD;
&#xD;
          -  Resting ejection fraction ‚â• 50% by MUGA or echocardiogram&#xD;
&#xD;
          -  No prior history of cardiac toxicity after receiving anthracycline therapy (e.g.,&#xD;
             doxorubicin hydrochloride, daunorubicin hydrochloride, or mitoxantrone hydrochloride)&#xD;
&#xD;
          -  No uncontrolled pulmonary disease&#xD;
&#xD;
          -  No symptomatic pulmonary disease requiring oxygen or medications&#xD;
&#xD;
          -  DLCO (i.e., oxygen diffusion capacity) ‚â• 80% on pulmonary function testing&#xD;
&#xD;
          -  Resting and exercise oxygen saturation ‚â• 90% by pulse oximetry&#xD;
&#xD;
          -  No ongoing pulmonary symptoms ‚â• grade 2 including any of the following:&#xD;
&#xD;
               -  Dyspnea on or off exertion&#xD;
&#xD;
               -  Paroxysmal nocturnal dyspnea&#xD;
&#xD;
               -  Significant pulmonary disease including chronic obstructive or restrictive&#xD;
                  pulmonary disease&#xD;
&#xD;
               -  No prior history of pulmonary toxicity after bleomycin or carmustine&#xD;
&#xD;
          -  No Medicare requirement for home oxygen (e.g., Resting O_2 saturation ‚â• 90% or&#xD;
             desaturation to ‚â• 90% with exertion)&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No preexisting sensory or motor peripheral neuropathy ‚â• grade 2&#xD;
&#xD;
          -  No history of allergic reaction to eggs&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No other uncontrolled illness&#xD;
&#xD;
          -  Prior stem cell transplantation for relapsed or refractory disease allowed&#xD;
&#xD;
          -  At least 2 weeks since prior immunotherapy and recovered&#xD;
&#xD;
          -  At least 2 weeks since prior chemotherapy (excluding hydroxyurea) and recovered&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
          -  No concurrent routine corticosteroids except for treatment of other medical problems&#xD;
             (e.g., pulmonary, rheumatologic, or adrenal disorders)&#xD;
&#xD;
          -  At least 2 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No prior radiotherapy that potentially included the heart in the field (e.g., mantle)&#xD;
&#xD;
          -  No prior history of chest radiation&#xD;
&#xD;
          -  No concurrent palliative radiotherapy&#xD;
&#xD;
          -  At least 2 weeks since prior investigational therapy&#xD;
&#xD;
          -  Prior bortezomib allowed&#xD;
&#xD;
          -  No other concurrent commercial or investigational agents or therapies for the&#xD;
             malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristie Blum</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>February 7, 2005</study_first_submitted>
  <study_first_submitted_qc>February 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2005</study_first_posted>
  <last_update_submitted>June 3, 2013</last_update_submitted>
  <last_update_submitted_qc>June 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Mycosis Fungoides</mesh_term>
    <mesh_term>Sezary Syndrome</mesh_term>
    <mesh_term>Leukemia, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
    <mesh_term>Leukemia-Lymphoma, Adult T-Cell</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
    <mesh_term>Leukemia, Monocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Megakaryoblastic, Acute</mesh_term>
    <mesh_term>Leukemia, Erythroblastic, Acute</mesh_term>
    <mesh_term>Leukemia, Basophilic, Acute</mesh_term>
    <mesh_term>Leukemia, Eosinophilic, Acute</mesh_term>
    <mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
    <mesh_term>Hypereosinophilic Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

